Details for New Drug Application (NDA): 202517
✉ Email this page to a colleague
NDA 202517 describes TELMISARTAN AND AMLODIPINE, which is a drug marketed by Alembic, Lupin Ltd, Mylan, and Torrent, and is included in four NDAs. It is available from two suppliers. Additional details are available on the TELMISARTAN AND AMLODIPINE profile page.
The generic ingredient in TELMISARTAN AND AMLODIPINE is amlodipine besylate; telmisartan. There are fifty drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the amlodipine besylate; telmisartan profile page.
The generic ingredient in TELMISARTAN AND AMLODIPINE is amlodipine besylate; telmisartan. There are fifty drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the amlodipine besylate; telmisartan profile page.
Summary for 202517
| Tradename: | TELMISARTAN AND AMLODIPINE |
| Applicant: | Torrent |
| Ingredient: | amlodipine besylate; telmisartan |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 5MG BASE;40MG | ||||
| Approval Date: | Jan 8, 2014 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 10MG BASE;40MG | ||||
| Approval Date: | Jan 8, 2014 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 5MG BASE;80MG | ||||
| Approval Date: | Jan 8, 2014 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
